The 2022 update on global cancer statistics reveals a staggering 20 million new cancer diagnoses and nearly 10 million deaths. These figures, derived from the Global Cancer Observatory, highlight the importance of population-based cancer survival as a key metric for evaluating health system performance. However, the quality and representativeness of data are crucial, with only a small percentage of countries in Africa, Asia, South America, and Central America collecting sufficient data. This lack of high-quality, country-specific cancer registries, particularly in low-income and middle-income countries (LMICs), can lead to underestimations of cancer incidence and mortality. The report also emphasizes the inequity in access to effective prevention and screening methods, such as lung cancer and breast cancer. Georgia, for example, has made significant strides in tobacco control and cancer screening, but challenges remain, including low uptake rates and the influence of the tobacco industry. In Bangladesh, efforts are still in their early stages, with limited access to modern cancer treatments and drug development. Despite these challenges, international partnerships and efforts, such as the World Health Organization's Essential Medication List, can help improve access to cancer treatments. In LMICs, in-country production capabilities for biosimilar drugs can significantly impact cancer care. The authors stress the importance of coordinated and sustained data collection and collaboration to ensure global equity in cancer screening, treatment, and post-cancer care, ultimately contributing to a healthier population worldwide.The 2022 update on global cancer statistics reveals a staggering 20 million new cancer diagnoses and nearly 10 million deaths. These figures, derived from the Global Cancer Observatory, highlight the importance of population-based cancer survival as a key metric for evaluating health system performance. However, the quality and representativeness of data are crucial, with only a small percentage of countries in Africa, Asia, South America, and Central America collecting sufficient data. This lack of high-quality, country-specific cancer registries, particularly in low-income and middle-income countries (LMICs), can lead to underestimations of cancer incidence and mortality. The report also emphasizes the inequity in access to effective prevention and screening methods, such as lung cancer and breast cancer. Georgia, for example, has made significant strides in tobacco control and cancer screening, but challenges remain, including low uptake rates and the influence of the tobacco industry. In Bangladesh, efforts are still in their early stages, with limited access to modern cancer treatments and drug development. Despite these challenges, international partnerships and efforts, such as the World Health Organization's Essential Medication List, can help improve access to cancer treatments. In LMICs, in-country production capabilities for biosimilar drugs can significantly impact cancer care. The authors stress the importance of coordinated and sustained data collection and collaboration to ensure global equity in cancer screening, treatment, and post-cancer care, ultimately contributing to a healthier population worldwide.